Interferon alfa-2b
From Wikipedia, the free encyclopedia
(Redirected from Interferon alfa 2b)
Jump to navigation
Jump to search
Interferon alfa-2bClinical data |
---|
MedlinePlus |
a690006
|
---|
License data |
|
---|
Pregnancy category |
US: C (Risk not ruled out)
|
---|
Routes of administration |
Subcutaneous, intramuscular |
---|
ATC code |
|
---|
Legal status |
---|
Legal status |
UK: POM (Prescription only)
US: ℞-only
|
---|
Identifiers |
---|
IUPHAR/BPS |
|
---|
DrugBank |
DB00105 N
|
---|
ChemSpider |
|
---|
ChEMBL |
CHEMBL1201558 N
|
---|
ECHA InfoCard |
100.208.165 |
---|
NY (what is this?) (verify)
|
---|
Interferon alfa 2b is an antiviral or antineoplastic drug, that was originally discovered in the laboratory of Charles Weissmann at the University of Zurich. It was developed at Biogen, and ultimately marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.
This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, Behçet's disease, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, mastocytosis and malignant melanoma.
Interferon alfa-2b products[1] |
---|
Product
|
Manufacturer
|
Features
|
Special uses
|
---|
Alpharona
|
Pharmaclon
|
|
|
Intron-A/IntronA
|
Schering-Plough
|
|
|
Realderon
|
Teva
|
|
|
Reaferon EC
|
GNC Vector
|
|
|
Reaferon EC-Lipint
|
Vector-Medica
|
liposomal
|
|
Infagel
|
Vector-Medica
|
ointment
|
|
Recolin
|
Vector-Medica
|
|
|
Altevir
|
Bioprocess subsidiary
|
liquid, free of HSA
|
|
Kipferon
|
Alfarm
|
combination with IgM, IgA, IgG
|
|
Giaferon
|
A/S Vitafarma
|
|
|
Genferon
|
Biocad
|
|
|
Opthalamoferon
|
Firn-M
|
with dimedrol
|
eye infections
|
See also[edit]
References[edit]
^ Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2* (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J. 2..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em
External links[edit]
- Intron-A Summary of Product Characteristics
Nagata S, Taira H, Hall A, et al. (Mar 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–20. doi:10.1038/284316a0. PMID 6987533.
Cell signaling: cytokines
|
---|
By family |
Chemokine |
CCL |
- CCL1
CCL2/MCP1
CCL3/MIP1α
CCL4/MIP1β
CCL5/RANTES
- CCL6
- CCL7
- CCL8
- CCL9
- CCL11
- CCL12
- CCL13
- CCL14
- CCL15
- CCL16
- CCL17
CCL18/PARC/DCCK1/AMAC1/MIP4
- CCL19
- CCL20
- CCL21
- CCL22
- CCL23
- CCL24
- CCL25
- CCL26
- CCL27
- CCL28
|
---|
CXCL |
CXCL1/KC
- CXCL2
- CXCL3
- CXCL4
- CXCL5
- CXCL6
- CXCL7
- CXCL8/IL8
- CXCL9
- CXCL10
- CXCL11
- CXCL12
- CXCL13
- CXCL14
- CXCL15
- CXCL16
- CXCL17
|
---|
CX3CL |
|
---|
XCL |
|
---|
|
---|
TNF |
- TNFA
Lymphotoxin
- TNFSF4
- TNFSF5/CD40LG
- TNFSF6
- TNFSF7
- TNFSF8
- TNFSF9
- TNFSF10
- TNFSF11
- TNFSF13
- TNFSF13B
- EDA
|
---|
Interleukin |
Type I (grouped by receptor subunit) |
γ chain |
IL2/IL15
IL4/IL13
- IL7
- IL9
- IL21
|
---|
β chain |
|
---|
IL6 like/gp130
|
|
---|
IL12 family/IL12RB1
|
|
---|
Other |
|
---|
|
---|
Type II |
IL10 family |
IL10/IL22
- IL19
- IL20
- IL24
- IL26
Interferon type III
|
---|
Interferon |
I |
- IFNA1
- IFNA2
- IFNA4
- IFNA5
- IFNA6
- IFNA7
- IFNA8
- IFNA10
- IFNA13
- IFNA14
- IFNA16
- IFNA17
- IFNA21
- IFNB1
- IFNK
- IFNW1
|
---|
II |
|
---|
|
---|
|
---|
Ig superfamily |
IL1 family: IL1A/IL1F1
- IL1B/IL1F2
- 1Ra/IL1F3
- IL1F5
- IL1F6
- IL1F7
- IL1F8
- IL1F9
- IL1F10
- 33/IL1F11
- 18/IL1G
|
---|
IL17 family |
|
---|
|
---|
Other |
Hematopoietic
- KITLG
- Colony-stimulating factor
- SPP1
- MIF
|
---|
|
---|
By function/ cell |
|
---|
Immunostimulants (L03)
|
---|
Endogenous |
Cytokines |
Colony-stimulating factors |
G-CSF
Filgrastim / Pegfilgrastim
- Lenograstim
GM-CSF
SCF
|
---|
Interferons |
alpha:
- Albinterferon
Interferon alfa natural
Interferon alfa 2a / Peginterferon alfa-2a
Interferon alfa 2b / Peginterferon alfa-2b
- Interferon alfa n1
- Interferon alfacon-1
- Interferon alpha-n3
beta:
Interferon beta natural
- Interferon beta 1a
- Interferon beta 1b
- Interferon gamma
|
---|
Interleukins |
|
---|
|
---|
Other protein / peptide |
- Growth hormone
- Immunocyanin
- Pegademase
- Prolactin
- Tasonermin
|
---|
Other |
- Female sex steroids
- Histamine dihydrochloride
- Poly ICLC
- Vitamin D
|
---|
|
---|
Exogenous |
beta-glucan
heterocyclic compound
hydroxyquinoline
- Mifamurtide
oligopeptides
- Glatiramer acetate
- Thymopentin
- Thymosin α1
- Thymulin
polyribonucleotide
- Polyinosinic:polycytidylic acid
thiazolidine
vaccines
- Bacillus Calmette–Guérin
- Melanoma vaccine
- Sipuleucel-T
|
---|
DNA virus antivirals (primarily J05, also S01AD and D06BB)
|
---|
Baltimore I |
Herpesvirus |
DNA-synthesis inhibitor |
TK activated |
Purine analogue |
guanine (Aciclovir#/Valaciclovir
Ganciclovir/Valganciclovir#
Penciclovir/Famciclovir)
|
---|
Pyrimidine analogue |
uridine (Idoxuridine
Trifluridine (+tipiracil)
Edoxudine)
|
---|
|
---|
Not TK activated |
|
---|
|
---|
Other |
- Docosanol
early protein (Fomivirsen)
- Tromantadine
|
---|
|
---|
HPV/MC
|
Imiquimod/Resiquimod
- Podophyllotoxin
|
---|
Vaccinia |
|
---|
Poxviridae |
|
---|
|
---|
Hepatitis B (VII) |
Nucleoside analogues/NARTIs: Entecavir#
- Lamivudine
- Telbivudine
- Clevudine
Nucleotide analogues/NtRTIs: Adefovir
- Tenofovir disoproxil
- Tenofovir alafenamide
|
---|
Multiple/general |
Nucleic acid inhibitors |
|
---|
Interferon |
- Interferon alfa 2b
- Peginterferon alfa-2a
|
---|
Multiple/unknown |
Ribavirin#/Taribavirin†
- Moroxydine
|
---|
|
---|
#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III
|
RNA virus antivirals (primarily J05, also S01AD and D06BB)
|
---|
Hepatitis C |
NS3/4A protease inhibitors (–previr) |
- Asunaprevir
Boceprevir‡
Ciluprevir§
Danoprevir†
Faldaprevir‡
- Glecaprevir
- Grazoprevir
- Narlaprevir
- Paritaprevir
Simeprevir#
Sovaprevir†
Telaprevir‡
- Vaniprevir
Vedroprevir§
- Voxilaprevir
|
---|
NS5A inhibitors (–asvir) |
Daclatasvir#
- Elbasvir
- Ledipasvir
Odalasvir†
- Ombitasvir
- Pibrentasvir
Ravidasvir†
Ruzasvir†
Samatasvir†
- Velpatasvir
|
---|
NS5B RNA polymerase inhibitors (–buvir) |
Beclabuvir†
Dasabuvir#
Deleobuvir§
Filibuvir§
Setrobuvir§
Sofosbuvir#
Radalbuvir†
Uprifosbuvir†
|
---|
Combination drugs |
- Elbasvir/grazoprevir
- Glecaprevir/pibrentasvir
Ledipasvir/sofosbuvir#
Ombitasvir/paritaprevir/ritonavir#
- Sofosbuvir/daclatasvir
- Sofosbuvir/velpatasvir/voxilaprevir
- Velpatasvir/sofosbuvir
|
---|
|
---|
Picornavirus |
|
---|
Anti-influenza agents |
adamantane derivatives/M2 inhibitors (Adapromine
- Amantadine
Rimantadine)
neuraminidase inhibitors/release phase (Oseltamivir#
- Zanamivir
Peramivir, Laninamivir†)
|
---|
Multiple/general |
Interferon |
- Interferon alfa 2b
Peginterferon alfa-2a#
|
---|
Multiple/unknown |
BCX4430†
- Favipiravir
Remdesivir†
Mericitabine†
MK-608§
NITD008§
- Moroxydine
Ribavirin#/Taribavirin†
- Triazavirin
|
---|
|
---|
#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III
|
Cytokine receptor modulators
|
---|
Chemokine |
|
---|
CSF |
Erythropoietin |
Agonists: ARA-290
- Asialo erythropoietin
- Carbamylated erythropoietin
- CNTO-530
- Darbepoetin alfa
- Epoetin alfa
- Epoetin beta
- Epoetin delta
- Epoetin epsilon
- Epoetin gamma
- Epoetin kappa
- Epoetin omega
- Epoetin theta
- Epoetin zeta
- Erythropoietin (EPO)
- Erythropoietin-Fc
- Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)
- Peginesatide
- Pegol sihematide (EPO-018B)
|
---|
G-CSF (CSF3) |
Agonists: Filgrastim
- Granulocyte colony-stimulating factor
- Lenograstim
- Leridistim
- Lipegfilgrastim
- Nartograstim
- Pegfilgrastim
- Pegnartograstim
|
---|
GM-CSF (CSF2) |
Agonists: Ecogramostim
- Granulocyte macrophage colony-stimulating factor
- Milodistim
- Molgramostim
- Regramostim
- Sargramostim
Antibodies: Mavrilimumab
- MOR103
- Namilumab
|
---|
M-CSF (CSF1) |
Agonists: Cilmostim
- Interleukin-34
- Lanimostim
- Macrophage colony-stimulating factor
- Mirimostim
Kinase inhibitors: Agerafenib
|
---|
SCF (c-Kit) |
|
---|
Thrombopoietin |
Agonists: Eltrombopag
- Pegacaristim
- Promegapoietin
- Romiplostim
- Thrombopoietin (THPO, MGDF)
|
---|
|
---|
Interferon |
IFNAR (α/β, I) |
Agonists: Albinterferon
- Interferon alpha (interferon alfa, IFN-α)
Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)
- Interferon alfa 2a
- Interferon alfa 2b
- Interferon alfa n1
- Interferon alfacon-1
- Interferon alpha-n3
Interferon beta (IFN-β) (IFNB1, IFNB3)
- Interferon beta 1a
- Interferon beta 1b
- Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
- Interferon omega (IFN-ω, IFNW1)
- Peginterferon alfa-2a
- Peginterferon alfa-2b
Antibodies: Anifrolumab
- Faralimomab
- MEDI-545
- Rontalizumab
- Sifalimumab
Decoy receptors: Bifarcept
|
---|
IFNGR (γ, II) |
Agonists: Interferon gamma (IFN-γ)
- Interferon gamma 1b
Antibodies: Emapalumab
- Fontolizumab
|
---|
IFNLR (λ, III) |
- See IL-28R (IFNLR) here instead.
|
---|
|
---|
Interleukin |
|
---|
TGFβ |
|
---|
TNF |
|
---|
Others |
JAK (inhibitors)
|
JAK1 |
- Baricitinib
- Filgotinib
- Momelotinib
- Oclacitinib
- Ruxolitinib
- Tofacitinib (tasocitinib, CP-690550)
- Upadacitinib
|
---|
JAK2 |
- AG-490
- Atiprimod
- AZD-1480
- Baricitinib
- CHZ868
- Cucurbitacin I (elatericin B, JSI-124)
- CYT387
- Lestaurtinib
- NSC-7908
- NSC-33994
- Pacritinib
- Ruxolitinib
- SD-1008
- Tofacitinib (tasocitinib, CP-690550)
|
---|
JAK3 |
- AG-490
- Cercosporamide
- TCS-21311
- Tofacitinib (tasocitinib, CP-690550)
- WHI-P 154
- ZM-39923
- ZM-449829
|
---|
|
---|
Others |
Additional cytokines: Cardiotrophin 1 (CT-1)
- FMS-like tyrosine kinase 3 ligand (FLT3L)
- Leukemia/leukocyte inhibitory factor (LIF)
- Oncostatin M (OSM)
- Thymic stromal lymphopoietin (TSLP)
Additional cytokine receptor modulators: Emfilermin
- Lestaurtinib
- Midostaurin
- Quizartinib
- Sorafenib
- Sunitinib
|
---|
|
---|
- See also
- Receptor/signaling modulators
- Signaling peptide/protein receptor modulators
- Growth factor receptor modulators
|
Categories:
- Antivirals
- Antiinfective agent stubs
- Antineoplastic and immunomodulating drug stubs
Hidden categories:
- Articles with changed DrugBank identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles with changed EBI identifier
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drug has EMA link
- Drugboxes which contain changes to verified fields
- All stub articles
Navigation menu
Personal tools
- Not logged in
- Talk
- Contributions
- Create account
- Log in
Navigation
- Main page
- Contents
- Featured content
- Current events
- Random article
- Donate to Wikipedia
- Wikipedia store
Interaction
- Help
- About Wikipedia
- Community portal
- Recent changes
- Contact page
Tools
- What links here
- Related changes
- Upload file
- Special pages
- Permanent link
- Page information
- Wikidata item
- Cite this page
Print/export
- Create a book
- Download as PDF
- Printable version
Languages
- Català
- Русский
- Српски / srpski
- Srpskohrvatski / српскохрватски
Edit links
(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.592","walltime":"0.727","ppvisitednodes":"value":4784,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":264637,"limit":2097152,"templateargumentsize":"value":2595,"limit":2097152,"expansiondepth":"value":16,"limit":40,"expensivefunctioncount":"value":2,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":4411,"limit":5000000,"entityaccesscount":"value":2,"limit":400,"timingprofile":["100.00% 545.520 1 -total"," 70.44% 384.274 1 Template:Drugbox"," 49.98% 272.629 1 Template:Infobox"," 21.69% 118.305 24 Template:Navbox"," 13.64% 74.428 16 Template:Unbulleted_list"," 12.63% 68.872 2 Template:Cite_journal"," 7.26% 39.590 1 Template:Infobox_drug/chemical_formula"," 4.71% 25.683 1 Template:Interferons"," 3.59% 19.606 1 Template:Chem_molar_mass"," 2.86% 15.578 1 Template:DNA_antivirals"],"scribunto":"limitreport-timeusage":"value":"0.195","limit":"10.000","limitreport-memusage":"value":4697212,"limit":52428800,"cachereport":"origin":"mw1319","timestamp":"20181010161735","ttl":1900800,"transientcontent":false);mw.config.set("wgBackendResponseTime":77,"wgHostname":"mw1252"););